Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | CES1 | P23141 | 2/20 | 0.50 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.40 |
| ▸ | SHBG | P04278 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4102499 | 1.00 | CES2 (0.50) | CES2CES1UGT2B7PDPK1AKR1C3 | |
| SCHEMBL1318569 | 1.00 | CES2 (0.50) | CES2CES1UGT2B7PDPK1AKR1C3 | |
| SCHEMBL11622406 | 0.83 | AKR1C3 (0.46) | CES2CES1UGT2B7AKR1C3AKR1C2 | |
| SCHEMBL31074251 | 0.82 | ADRB1 (0.58) | UGT2B7SHBGADRA2BADRB1ADRA2A | |
| SCHEMBL20488728 | 0.82 | AKR1C3 (0.49) | UGT2B7AKR1C3AKR1C2SHBGPTGS1 | |
| SCHEMBL8251464 | 0.82 | UGT2B7 (0.45) | CES2CES1UGT2B7AKR1C3AKR1C2 | |
| SCHEMBL31621805 | 0.82 | CES2 (0.47) | CES2CES1PDPK1AKR1C3AKR1C2 | |
| SCHEMBL12891898 | 0.82 | CES2 (0.47) | CES2CES1PDPK1AKR1C3AKR1C2 | |
| SCHEMBL1926385 | 0.82 | AKR1C3 (0.49) | UGT2B7AKR1C3AKR1C2SHBGPTGS1 | |
| SCHEMBL13311775 | 0.80 | SLC6A2 (0.49) | UGT2B7APPKMT2AMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12540131-B2 | N-(heteroaryl) quinazolin-2-amine derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME LLC (US) | 2026-02-03 | — | — | US | claimed |
| US-20230023066-A1 | N-(HETEROARYL) QUINAZOLIN-2-AMINE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2023-01-26 | — | — | US | claimed |
| CN-107892693-A | A kind of preparation method of ticagrelor | 安徽诺全药业有限公司 | 2018-04-10 | — | — | CN | claimed |
| CN-107814692-A | A kind of ticagrelor key intermediate and preparation method thereof | 安徽诺全药业有限公司 | 2018-03-20 | — | — | CN | claimed |
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | claimed |
| US-20260000642-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | TAY THERAPEUTICS LTD (GB) | 2026-01-01 | — | — | US | disclosed |
| US-20250263370-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | Tay Therapeutics Limited (GB) | 2025-08-21 | — | — | US | disclosed |
| EP-4558224-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | Tay Therapeutics Limited (GB) | 2025-05-28 | — | — | EP | disclosed |
| US-20250114374-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2025-04-10 | — | — | US | disclosed |
| US-12187741-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2025-01-07 | — | — | US | disclosed |
| WO-2024018423-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | Tay Therapeutics Limited (GB) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023122000-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2012128582-A2 | A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HYUNDAI PHARM CO., LTD. (KR) | 2012-09-27 | — | — | WO | disclosed |
| WO-2012128582-A2 | A COMPOUND FOR INHIBITING HUMAN 11-β-HYDROXY STEROID DEHYDROGENASE TYPE 1, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HYUNDAI PHARM CO., LTD. (KR) | 2012-09-27 | — | — | WO | disclosed |
| US-20110172336-A1 | FLUOROCOPOLYMER COMPOSITION AND ITS PRODUCTION PROCESS | ASAHI GLASS COMPANY, LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2338935-A1 | FLUORINE-CONTAINING COPOLYMER COMPOSITION AND PROCESS FOR PRODUCTION THEREOF | ASAHI GLASS COMPANY, LIMITED (JP) | 2011-06-29 | — | — | EP | disclosed |
| US-20080009506-A1 | Imidazole Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-01-10 | — | — | US | disclosed |
| US-6329405-B1 | AS ILEAL BILE ACID TRANSPORTER INHIBITOR, FOR THERAPY OF HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 2001-12-11 | — | — | US | disclosed |
| CN-1287117-A | Cyclobutene derivatives, preparation method and therapeutic use thereof | SANKYO CO (JP) | 2001-03-14 | — | — | CN | disclosed |
| EP-1070703-A1 | Cyclobutene derivatives | Sankyo Company Limited (JP) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540131-B2 | N-(heteroaryl) quinazolin-2-amine derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | LRRK2, PARK7, SNCA | CES2 2482/4885CES1 2450/4885UGT2B7 3406/4885 |
| US-20250114374-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | CES2 4143/4885CES1 3778/4885UGT2B7 2124/4885 |
| US-12187741-B2 | Glycosidase inhibitors | GAA, ENGASE, GBA3 | CES2 318/4885CES1 467/4885UGT2B7 506/4885 |
| US-20230023066-A1 | N-(HETEROARYL) QUINAZOLIN-2-AMINE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, CLK2, PARK7 | CES2 3697/4885CES1 4421/4885UGT2B7 3007/4885 |
| US-20260000642-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | BET1, BRD4, PHKB | CES2 2325/4885CES1 2001/4885UGT2B7 3943/4885 |
| US-20080009506-A1 | Imidazole Compound | KCNH2, KCNJ2, KCNH3 | CES2 3454/4885CES1 3115/4885UGT2B7 1892/4885 |
| US-20250263370-A1 | PYRROLES AND IMIDAZOLES AS BET PROTEIN INHIBITORS | BET1, PHKB, BRD4 | CES2 4265/4885CES1 3291/4885UGT2B7 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.